Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional) | PAR 18 530

Frequently Asked Questions (FAQs)

What is the name and ID of this NIH funding opportunity?

The opportunity is titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)" and is identified as PAR-18-530.

What is the main goal of PAR-18-530?

The main goal is to translate promising scientific and engineering advances beyond early proof-of-concept into practical tools that can realistically be deployed by researchers, clinicians, and other end users. The focus is on development work that makes a technology truly usable in real pre-clinical, clinical, or other applied settings.

What kinds of projects does this FOA want to support?

This FOA supports projects that mature a technology, method, assay, device, or system that has already shown feasibility and move it toward being ready for use in the intended setting. That includes refinement, optimization, robustness and reproducibility work, and performance validation in relevant environments.

What does "translation" mean in the context of this FOA?

Translation here means taking something that "can work" and advancing it to the point where it is ready to be used as intended. The emphasis is on practical readiness, including meeting user needs, fitting real workflows, and demonstrating reliable performance under realistic conditions.

Does the FOA focus only on diagnosis technologies, or treatment technologies too?

It covers technologies for both diagnosis and treatment. More broadly, it supports tools and approaches that improve understanding of disease biology and pathology and/or strengthen applied capabilities such as risk assessment, detection, prevention, diagnosis, treatment, management, and monitoring of disease status, as long as the topic aligns with the missions of participating NIH institutes.

Is an academic-industry partnership required?

Yes. A defining feature of this FOA is the required partnership structure. Applications are expected to be submitted by an interdisciplinary, multi-institutional team operating in a strategic alliance that explicitly combines at least one academic organization and at least one industrial organization.

What does NIH mean by a "strategic alliance" in this FOA?

The partnership is expected to function as a coordinated development team with a coherent plan. The FOA emphasizes that the relationship should not be a set of loosely connected collaborators; instead, it should be organized to bridge common translation gaps and deliver a validated, user-ready solution.

Why does NIH require both academic and industrial partners?

The stated purpose is to bridge gaps that can slow translation, including differences in technical expertise, development experience, manufacturing or design controls knowledge, validation practices, and understanding of user needs and real-world workflows.

How important are end users and real-world workflows to this FOA?

They are central. Applicants are expected to plan, design, and validate the solution with a strong focus on suitability for end users, including who will use it, in what environment, and under what constraints (for example, clinical workflow, laboratory throughput, operating conditions, usability, reliability, and performance expectations).

What types of development activities can the budget support?

The FOA allows budgets to support activities such as enhancing or adapting an existing approach, optimizing performance, establishing robustness and reproducibility, and validating performance in relevant environments.

How does this FOA define "innovation"?

Innovation is framed pragmatically: not only novelty on paper, but the likelihood of delivering a new capability that end users can actually benefit from. The emphasis suggests that reviewer attention will likely be on development milestones, clear performance metrics, validation plans, and credible pathways to adoption.

Are clinical trials allowed under this funding opportunity?

Yes. Clinical trials are optional under this R01, but they are allowed when they directly support translation of the technology, method, or tool.

What kinds of clinical trials fit the intent of this FOA?

In this context, supported clinical trials would generally test functionality or validate performance of the tool or method in the intended real-world setting, as part of maturing and validating the technology.

What types of projects are not the focus of this FOA?

The FOA is not meant to support commercial-scale production, exploratory basic research that is not tied to a translational endpoint, or conventional clinical trials where translation of a technology is not the primary driver. Even when a study involves humans, it should be anchored in technology or method maturation and validation, rather than functioning as a stand-alone therapeutic efficacy trial with no central technology-development component.

What NIH grant mechanism is used?

This is an NIH discretionary grant using the R01 mechanism, with clinical trial participation labeled as optional depending on project needs.

Who is eligible to apply?

Eligibility is broad and includes many organization types across public, private, and nonprofit sectors, including state, county, and local governments; special districts; independent school districts; public and private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations (other than small businesses) and small businesses; and other entities.

Are minority-serving institutions and community-based organizations included in the eligible applicant categories?

Yes. The FOA highlights additional eligible categories such as HBCUs, Hispanic-serving Institutions, Tribal Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISISs). It also includes faith-based or community-based organizations, regional organizations, U.S. territories or possessions, federal agencies, non-U.S. (foreign) organizations, and other eligible entities listed in the opportunity description.

Is a for-profit company allowed to participate?

Yes. For-profit organizations are listed among eligible applicants, including small businesses and for-profit organizations other than small businesses. The FOA also expects at least one industrial organization to be part of the required partnership structure.

Are non-U.S. (foreign) organizations eligible?

Yes. Non-U.S. (foreign) organizations are explicitly mentioned among eligible applicant categories in the provided opportunity description.

What CFDA numbers are associated with this opportunity?

The opportunity is associated with CFDA numbers 93.286, 93.394, 93.395, and 93.847.

When was this opportunity created, and what is the closing date shown in the source listing?

The opportunity was created on 2017-12-21. The source listing notes an original closing date of 2021-03-25, and applicants are advised to verify current status in NIH notices and the active FOA record because opportunities can be reissued, updated, or replaced.

What is the overall theme reviewers are likely to prioritize?

Based on the FOA description, the overall theme is development-focused translation: credible academic-industrial coordination, clear development milestones, measurable performance metrics, robust validation in relevant settings, and a practical pathway to end-user adoption.